Plethora Solutions Holdings Plc Regulatory News (PLE)

8 May 2007 07:02

Plethora Solutions Holdings PLC08 May 2007 PLETHORA SOLUTIONS HOLDINGS PLC Timm Medical Acquires Marketing Rights to Two Additional Products. Plethora Solutions Holdings PLC ("Plethora", AIM: PLE), a company specialisingin the development and marketing of products for the treatment and management ofurological disorders, today announces that its US subsidiary, Timm MedicalTechnologies, Inc. ('Timm'), has acquired marketing rights to two new products;the ActicufTM device for the management of light to moderate male urinaryincontinence and the Midstream Cleancatch(R) device for the collection ofmidstream urine samples. ActicufTM is a simple to apply, discrete and disposable device designed to helpprevent urine leakage in men suffering from urinary incontinence, a conditionaffecting more than two million men in the USA. Timm has secured internationalmarketing rights to the product and has already achieved first sales of theproduct in the USA. A large number of men are either transiently or permanentlyafflicted with some degree of bladder leakage. In circumstances where treatmentis either ineffective or not available then ActicufTM may provide a highlyeffective and safe alternative for the management of the condition. Midstream Cleancatch(R) is a collection device, for the collection of midstreamurine samples in men and women. Midstream urine samples (MSU) are collectedroutinely as part of the diagnosis and management of urological and otherdisorders. It is estimated that there are over 70 million urine samplescollected every year in the UK alone. This novel device has been provenclinically to reduce contamination rates and spillage and improve diagnosis. Itis designed to help standardise sample collection, make sampling easier andcleaner for the patient and the health care worker. The product is already beingused in some parts of the UK's National Health Service and Timm will launch theproduct through its US sales force and international distribution network in thecoming months. Steven Powell, Plethora CEO, commented: "The Timm operation has made substantial progress with the marketing of itsErecAid(R) and Rigiscan(R) products for the treatment and management of erectiledysfunction. We believe that the time is right to begin to implement the nextphase of our growth strategy for Timm which is to utilise its sales andmarketing capability to market a broader portfolio of urology products and, inso doing, accelerate revenue growth". -Ends- For further information contact: Plethora Solutions Tel : 020 7269 8630Steven Powell City/Financial Enquiries Tel: 020 7379 5151MaitlandBrian Hudspith/Liz Morley Scientific/Trade Press Enquiries Tel: 020 7861 3838De Facto CommunicationsRichard Anderson About Plethora Solutions: Plethora is focused on the development and marketing of products for thetreatment of urological disorders. The Company has products in clinicaldevelopment for the treatment of overactive bladder, stress urinaryincontinence, interstitial cystitis, gynaecological pain and prematureejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based TimmMedical Technologies Inc which markets the ErecAid(R) and Rigiscan(R) productsfor the treatment of erectile dysfunction (ED) to urology clinics through aUS-based specialty sales team. Most recently, the ErecAid has been found to beeffective for men that fail Medical Management and for men recovering fromprostatectomy The Company is headquartered in the UK and is listed on the LondonStock Exchange (AIM:PLE) Further information is available atwww.plethorasolutions.co.uk This information is provided by RNS The company news service from the London Stock Exchange